COG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

**FAST FACTS**
Eligibility Reviewed and Verified By
______________________ MD/DO/RN/LPN/CRA Date _________
______________________ MD/DO/RN/LPN/CRA Date _________
Consent Version Dated___________

PATIENT ELIGIBILITY:
**Important note:** The eligibility criteria listed below are interpreted literally and cannot be waived (per COG policy posted 5/11/01). All clinical and laboratory data required for determining eligibility of a patient enrolled on this trial must be available in the patient’s medical research record which will serve as the source document for verification at the time of audit.

___1. Pre-Enrollment Eligibility Screening (Step 0)
   Patients must be consented and enrolled on APEC14B1 followed by same day enrollment on the ACNS1422 Pre-Enrollment Eligibility Screening (Step 0) to complete the RAPID CENTRAL PATHOLOGY REVIEW.
   The APEC14B1 Part A consent will cover the pre-enrollment eligibility screening (including pathology, molecular, and imaging central reviews) for ACNS1422. See Appendix IV, Section 3.1.1, and Section 14.0.

Pre-Enrollment Eligibility Screening Criteria
The following criteria must be met prior to initiating the pre-enrollment eligibility screening criteria on ACNS1422 (Step 0).

___2. Age - Patients must be greater than or equal to 3 years and less than 22 years of age at the time of enrollment on ACNS1422 Step 0.

___3. Diagnosis - Patient is suspected to have newly diagnosed average-risk medulloblastoma by institutional diagnosis. Please note: Patients with a pending result of CSF cytology tests are eligible for enrollment on APEC14B1 and enrollment on the ACNS1422 Pre-Enrollment Eligibility Screening (Step 0).

___4. Consent - Patient and/or their parents or legal guardians have signed informed consent for APEC14B1 Part A.
5. Specimen Submission
The following specimens are projected to be submitted through APEC14B1 ASAP, preferably within 15 days of definitive surgery. See the APEC14B1 Manual of Procedures for further instructions and shipping details.

### Required Materials to be Submitted on APEC14B1

<table>
<thead>
<tr>
<th>Sample</th>
<th>When Obtained</th>
<th>Study to be Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral Blood (5 ml of blood in a purple top tube [EDTA])</td>
<td>At time of diagnosis</td>
<td>Sanger sequencing for mutations in CTNNB1 (the gene encoding β-catenin) on germline DNA to determine if a sequence change is somatic or germline</td>
</tr>
<tr>
<td>Formalin Fixed Paraffin Embedded (FFPE) Sections:</td>
<td>At time of diagnosis</td>
<td></td>
</tr>
<tr>
<td>• 1 H&amp;E stained slide from all available paraffin blocks</td>
<td></td>
<td>1) IHC: β-catenin</td>
</tr>
<tr>
<td>Cut sequentially from one block (most representative block):</td>
<td></td>
<td>2) Sanger sequencing for mutations in CTNNB1 (the gene encoding β-catenin)</td>
</tr>
<tr>
<td>• 15 (5µm) unstained slides</td>
<td></td>
<td>3) FISH studies: MYCN and MYC amplification</td>
</tr>
<tr>
<td>• 20 (10µm) scrolls (2 tubes of 10 each)</td>
<td></td>
<td>4) DNA methylation array</td>
</tr>
</tbody>
</table>

Institutional Pathology Report (may submit preliminary report for initiation of central review, submit final once available)

• Must include definitive results for INI1^, synaptophysin, and GFAP
IHC results if optional stained slides (see table below) are not sent.** Slides may still be requested at the central reviewers’ discretion.

---

APEC14B1 Specimen Transmittal Form*

* In order for the BPC to properly process specimens for testing, the APEC14B1 transmittal form must include information that the shipment includes specimens for Rapid Central Review for pre-screening on ACNS1422.

**Submission of immunohistochemical slides is strongly preferred, but if the immunohistochemical results are explicitly mentioned in the report then submission of the INI1, synaptophysin and GFAP stained slides is optional.

^ If a site does not have access to INI1 staining, this can be requested from the Nationwide Children’s Hospital Anatomic Pathology Laboratory for a fee. Please refer to the memo on Neurocognitive Testing and INI1 Staining posted on the study webpage on 12/15/2017 for full details.

---

6. Timing
Patients must begin treatment within 36 days of definitive surgery (Day 0).
Patients must be enrolled before treatment begins. The date protocol therapy is projected to start must be no later than five (5) calendar days after the date of study enrollment. Patients may begin therapy on the same day as enrollment.

---

7. All clinical and laboratory studies (but not including imaging studies) to determine eligibility must be performed within 14 days prior to enrollment unless otherwise indicated. Laboratory values used to assess eligibility must be no older than fourteen (14) days at the start of therapy. Laboratory tests need not be repeated if therapy starts within fourteen (14) days of obtaining labs to assess eligibility. If a post-enrollment lab value is outside the limits of eligibility, or laboratory values are > 14 days old, then the following laboratory evaluations must be re-checked within 48 hours prior to initiating therapy: CBC with differential, bilirubin, ALT (SGPT) and serum creatinine. If the recheck is outside the limits of eligibility, the patient may not receive protocol therapy and will be considered off protocol therapy.

---

8. Age - Patients must be greater than or equal to 3 years and less than 22 years at the time of enrollment.
9. **Diagnosis** - Patients must be newly diagnosed and have:
   - Eligibility confirmed by rapid central pathology and molecular screening review on APEC14B1 (See Section 3.1):
     - classical histologic type (non LC/A) WNT medulloblastoma
     - positive nuclear β-catenin by IHC
     - positive for CTNNB1 mutation
     - negative for MYC and MYCN by FISH.

   Please see exclusion criteria regarding metastatic disease in Section 3.3.8.1.

10. **CSF Cytology**
    Patient must have negative lumbar CSF cytology.

    **Note:** CSF cytology for staging should be performed no sooner than 14 days post operatively to avoid false positive CSF. Ideally, CSF should be obtained between Day 14 and Day 21 to allow for final staging status before enrollment onto the study. Patients with positive CSF cytology obtained 0 to 14 days after surgery should have cytology repeated to determine eligibility and final CSF status. Patients with negative CSF cytology from lumbar puncture obtained 0 to 14 days after surgery do not need cytology repeated. Patients with negative CSF cytology from lumbar puncture obtained prior to surgery do not need cytology repeated post-operatively.

11. **Imaging**
    **Patients must have eligibility confirmed by Rapid Central Imaging Review on APEC14B1. Patients must have ≤ 1.5 cm² maximal cross-sectional area of residual tumor (see Section 3.1.4).** Whole brain MRI with and without gadolinium (see Section 16.2) and spine MRI with gadolinium (see Section 16.3) must be performed. See Section 16.1 for required timepoints and Section 16.2, Table 16.1, and Table 16.2 for additional details required for Rapid Central Imaging Review.

12. **Timing**
    Patients must be enrolled, and protocol therapy must be projected to begin, no later than 36 days after definitive diagnostic surgery (Day 0). See Section 3.2.4.

13. **Organ Function Requirements**
    - **Adequate Bone Marrow Function Defined As:**
      - Peripheral absolute neutrophil count (ANC) ≥ 1000/μL
      - Platelet count ≥ 100,000/μL (transfusion independent)
      - Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)
    - **Adequate Renal Function Defined As:**
      - Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m² or
      - A serum creatinine based on age/gender as follows:

    | Age        | Maximum Serum Creatinine (mg/dL) |
    |------------|----------------------------------|
    |            | Male    | Female                   |
    | 3 to < 6 years | 0.8     | 0.8                      |
    | 6 to < 10 years | 1       | 1                        |
    | 10 to < 13 years | 1.2     | 1.2                      |
    | 13 to < 16 years | 1.5     | 1.4                      |
    | ≥ 16 years       | 1.7     | 1.4                      |

    The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC.

    - **Adequate Liver Function Defined As:**
      - Total or direct bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and
      - SGPT (ALT) ≤ 135 U/L (3x ULN). For the purpose of this study, the ULN for SGPT is 45 U/L
    - **Central Nervous System Function Defined As:**
      - Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled (see Section 4.2.2 for a list of anticonvulsants that should be avoided while receiving vincristine).
      - Patients must not be in status epilepticus, a coma or on assisted ventilation at the time of study enrollment.
14. **Language**
Patients must have receptive and expressive language skills in English, French, or Spanish to complete the QoL and Neurocognitive assessments (See Sections 3.2.5 and Appendix IX). If a patient meets these criteria but the parent/guardian speaks a language other than English, French, or Spanish, the patient may still be enrolled and tested, and the parent-report measures should be omitted.

**EXCLUSION CRITERIA:**
1. **Metastatic Disease**
   Patients with metastatic disease by either MRI evaluation (brain and spine) or lumbar CSF cytology are not eligible. **Patients who are unable to undergo a lumbar puncture for assessment of CSF cytology are ineligible.**
2. **Prior Therapy**
   Patients must not have received any prior radiation therapy or chemotherapy (tumor-directed therapy) other than surgical intervention and/or corticosteroids.
3. **Pregnancy and Breast Feeding**
   - Female patients who are pregnant are ineligible due to risks of fetal and teratogenic adverse events as seen in animal/human studies.
   - Lactating females are not eligible unless they have agreed not to breastfeed their infants.
   - Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.
   - Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation.
4. **Patients with a history of moderate to profound intellectual disability (i.e. IQ < 55) are not eligible for enrollment.**
   PLEASE NOTE: Children with a prior history of attention deficit hyperactivity disorder (ADHD) or a specific learning disability (e.g., dyslexia) are eligible for this study.
REQUIRED OBSERVATIONS:
Required Observations at Baseline and During Radiation Therapy
See Section 17.0 for Radiation Therapy Guidelines. Note: If patient is removed off protocol therapy see Section 7.1.
Observation
- History
- Physical exam, including height and weight
- Neurologic exam
- MRI of brain with and without gadolinium and MRI of spine with gadolinium
- CSF Cytology
- Audiogram or BAER (See Appendix X)
- Endocrine evaluation
- CBC, diff, platelets
- Serum creatinine or GFR or creatinine clearance based on age/gender (See Section 3.3.6.2)
- Electrolytes (including BUN, calcium, magnesium, sodium, potassium, phosphate), bilirubin, SGPT (ALT)
- Pregnancy test
1. All audiologic reports must be scanned and submitted electronically using the COG RAVE system within one week after the tests have been completed for retrospective central review.
2. Endocrine evaluation includes: thyroid function evaluation (free T4 and TSH), GH, IGF-1, IGFBP3 (if available), prolactin, LH, FSH, estradiol or testosterone (depending on pubertal status and sex).
3. Obtain in females of childbearing potential.

TREATMENT PLAN:
Overview of Treatment Plan
Specimens submitted for Central Review by Day 15 on APEC14B1 and ACNS1422 Pre-Enrollment Eligibility Screening (Step 0) See Section 3.1
Submit Imaging on APEC14B1 if tumor is positive for β-Catenin by IHC
Results available by Day 32
Study Enrollment on ACNS1422 (Step 1)
Definitive Surgical Resection XRT Starts XRT Ends
36 days 6 weeks
4 weeks 36 weeks
Week
Chemotherapy
Classification Phase Radiotherapy Phase Rest Phase Maintenance Phase
0 1 2 3 4 5 6 7 8 9 10 11 17 21 27 31 37 41
NO VINCristine A B A B A B A

Radiotherapy (6 Weeks) (See Section 4.3 for required observations during RT and Section 17.0 for RT guidelines)
XRT – 18 Gy CSI
36 Gy Boost to tumor bed (for a sum of 54 Gy)
Maintenance -7 Cycles of Chemotherapy - Alternating Cycles A and B
Cycle A (42 Days) Cycles 1, 3, 5, 7 (Section 4.4)
• CISplatin (75 mg/m²) IV over 6 hours on Day 1
• Lomustine (CCNU) (75 mg/m²) orally on Day 1
• VinCRIStine (1.5 mg/m², maximum dose 2 mg) IV push or infusion via minibag as per institutional policy on Days 1, 8, and 15

Cycle B (28 Days) Cycles 2, 4, 6 (Section 4.5)
• Cyclophosphamide (1000 mg/m²) IV over 30-60 minutes on Days 1 and 2
• VinCRIStine (1.5 mg/m², maximum dose 2 mg) IV push or infusion via minibag as per institutional policy on Days 1 and 8
• MESNA (200 mg/m²/dose) IV infusion over 15-30 minutes starting 15-30 minutes prior to or at the same time as cyclophosphamide and repeated at 4 and 8 hours on Days 1 and 2.

Enrollment on ACNS1422 must be preceded by central rapid pathology, molecular and imaging confirmation of average-risk WNT-driven medulloblastoma on APEC14B1.

Radiotherapy planning should begin as soon as possible to permit commencement of radiotherapy within 36 days of definitive surgery. Patients will receive 18 Gy craniospinal radiation, with a conformal boost to the tumor bed of 36 Gy for a sum of 54 Gy. See Sections 4.3 and 17.0.

Maintenance Chemotherapy (Sections 4.4 and 4.5) begins 4 weeks after completion of radiotherapy (Week 11) and when ANC ≥ 750/μl and platelets ≥ 75,000/μl. If a subject cannot begin maintenance therapy within 6 weeks of radiotherapy completion, then he/she will be taken off protocol therapy (See Section 8.1). Seven (7) cycles of chemotherapy will be delivered in an ABABABA pattern. A central venous access device is recommended prior to the start of Maintenance.


TOXICITIES AND DOSAGE MODIFICATIONS:
See Section 5.

SPECIMEN REQUIREMENTS:
Required Rapid Central Pathology Screening Review
Also see Section 15.

RAPID CENTRAL IMAGING REVIEW:
See above.